Drug Profile
Research programme: Parkinson's disease therapeutics - OPKO Health/Scripps Research Institute
Alternative Names: SR-3306Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer OPKO Health; The Scripps Research Institute
- Class Small molecules
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 09 Mar 2012 Preclinical trials in Parkinson's disease in USA (unspecified route)